A New Approach to Cancer Immunotherapy
Despite great progress has been made in cancer care, late-stage cancer still represents
a great challenge to modern medicine. Part of the challenge may be because more than
80% of late-stage cancer patients develop cancer cachexia. Cancer cachexia
significantly reduces patient’s response and tolerance to cancer treatment. More
importantly, the syndrome dramatically reduces patient’s quality of life thus brings
enormous suffering both to patients and their families. Due to the lack of treatment, the
syndrome directly kills 30% of cancer patients. Despite great efforts have been made to
develop treatments for cancer cachexia, all previous drug projects for cancer cachexia
have failed in clinical trials. We have conducted a series of elaborate studies to explore
how the tumor affects the host and inflicts cancer cachexia. Findings from our studies
reveal a new cause of cancer cachexia—tumor-induced immune disorder. This new
mechanism is shockingly consistent with and supported by strong clinical evidence. Our
approach to the development of therapeutics for cancer cachexia is focused on
modulating the immune disorder, and thus pioneering a new direction to develop cancer
immunotherapy. In this event, we will discuss this new approach to cancer
immunotherapy, through which we aim to develop breakthrough therapies of late-stage
cancer patients with cachexia.
Event Information
Event Topic:
A New Approach to Cancer Immunotherapy
Event Description:
Despite great progress has been made in cancer care, late stage cancer still represents a great challenge to modern medicine. Part of the challenge may be because more than 80% of late stage cancer patients develop cancer cachexia. Cancer cachexia significantly reduce patient’s response and tolerance to cancer treatment. More importantly the syndrome dramatically reduces patient’s quality of life thus brings enormous suffering both to patients and their families. Due to lack of treatment, the syndrome directly kills 30% of cancer patients. Despite great efforts have been made to develop treatments for cancer cachexia, all previous drug projects for cancer cachexia have failed in clinical trials. We have conducted a series of elaborate studies to explore how the tumor affects the host and inflicts cancer cachexia. Findings from our studies reveal a new cause of cancer cachexia—tumor induced immune disorder. This new mechanism is shockingly consistent with and supported by strong clinical evidence. Our approach to the development of therapeutics for cancer cachexia is focused on modulating the immune disorder, and thus pioneering a new direction to develop cancer immunotherapy. In this event, we will discuss this new approach to cancer immunotherapy, through which we aim to develop breakthrough therapies of late stage cancer patients with cachexia.
Date/Time:
Date(s) - 03/19/19
8:30 am - 10:30 am
Event Location:
NOVA - 505 West Olive Ave, Sunnyvale- Suite 799:
Speaker Information
Event Speaker:
Lingbing Zhang
Event Speaker Title:
Founder, CEO
Event Speaker Company:
Yinuoke Limited
Event Speaker Bio:
Dr. Zhang is the founder and CEO of Yinuoke Ltd, a clinical-stage biotech company developing first-in-class cancer immunotherapies based on the new concept of treating tumor-induced immune disorder (TID). Dr. Zhang graduated from Jilin University with a doctoral degree of immunology in 2007. From 2008 to 2012, Dr.Zhang did a postdoctoral fellowship at Stanford School of Medicine studying cancer immunology and immunotherapy. After the postdoctoral fellowship, Dr.Zhang continued to study cancer immunology for another four years at Stanford School of Medicine, focusing on the immune system dynamics during cancer progression and its impact on the host. In 2016, Dr.Zhang founded Yinuoke Ltd., to discover and develop innovative cancer immunotherapy by targeting TID.
Event Details
Cost:
$0
Add To Calendar
